Procyon Corporation (PCYN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4 | 5 | 5 | 5 | 5 | 7 | 5 | - |
| Operating profit | $m | -0 | -0 | ||||||
| Net profit | $m | 0 | 1 | -0 | -0 | -0 | 0 | -0 | - |
| EPS reported | $ | 0.00 | -0.04 | ||||||
| Operating cashflow per share | $ | -0.05 | -0.05 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.06 | -0.06 | ||||||
| Free cash flow | $m | -0 | -0 | ||||||
| Net debt | $m | -0 | -1 | ||||||
| Book value equity | $m | 2 | 2 | ||||||
| Book value per share | $ | 0.28 | 0.28 | ||||||
| Number of shares | m | 8.44 | 8.12 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 86.36 | - | ||||||
| P/B LTM | x | 0.66 | 0.68 | ||||||
| P/S LTM | x | 0.23 | 0.31 | ||||||
| P/FCF LTM | x | -3.12 | -12.36 | ||||||
| EV/EBITDA LTM | x | 5.78 | 16.14 | ||||||
| EV/Sales LTM | x | 0.24 | 0.33 | ||||||
| Earnings Yield LTM | % | +1.16% | +1.60% | ||||||
| FCF Yield | % | -32.03% | -8.09% | ||||||
| Quality | |||||||||
| ROE | % | +1.46% | +1.47% | ||||||
| ROIC | % | -17.53% | -17.53% | ||||||
| Operating margin | % | -6.69% | -6.69% | ||||||
| Gross margin | % | +31.86% | +31.86% | ||||||
| FCF/Sales | % | -7.42% | -7.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +33.89% | 0.00% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -3.56 | -0.39 | ||||||
| Net Debt/EBITDA | x | 0.21 | 0.21 | ||||||
| EBIT/Net interest | x | -1,236.93 | -1,236.93 | ||||||
| Net debt/market cap | % | +9.00% | +6.59% | ||||||
| Net debt/Equity | x | -0.12 | -0.40 | ||||||
| Gross debt/equity | x | 0.06 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Procyon Corporation, along with its affiliated entities, specializes in the development and distribution of proprietary medical solutions. Their primary focus is on addressing various skin conditions, including pressure and stasis ulcers, general wounds, dermatitis, inflammation, and other dermatological issues, predominantly within the United States. The company offers a diverse array of products. Under the AMERIGEL brand, they provide sophisticated skin and wound healing items such as hydrogel dressings, post-operative surgical kits, saline wound rinses, and protective lotions, in addition to hand sanitizer. Their HELIX3 line features Bioactive Collagen products, available in both powder and matrix forms. For comprehensive wound management, the AMERX brand includes various dressing types like calcium alginate, foam, gauze, and hydrocolloid, as well as complete wound care kits containing components like collagen matrix, collagen powder, foam, and hydrogel. Furthermore, Procyon markets compression garments under the EXTREMIT-EASE name. These offerings are distributed through multiple channels: to institutional clients such as hospitals, wound care clinics, nursing homes, home health agencies, and medical practitioners via distributors, and directly to individual consumers through online sales, direct purchases, and independent or chain pharmacies. Founded in 1987, the company's operations are headquartered in Clearwater, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Procyon Corporation, along with its affiliated entities, specializes in the development and distribution of proprietary medical solutions. Their primary focus is on addressing various skin conditions, including pressure and stasis ulcers, general wounds, dermatitis, inflammation, and other dermatological issues, predominantly within the United States. The company offers a diverse array of products. Under the AMERIGEL brand, they provide sophisticated skin and wound healing items such as hydrogel dressings, post-operative surgical kits, saline wound rinses, and protective lotions, in addition to hand sanitizer. Their HELIX3 line features Bioactive Collagen products, available in both powder and matrix forms. For comprehensive wound management, the AMERX brand includes various dressing types like calcium alginate, foam, gauze, and hydrocolloid, as well as complete wound care kits containing components like collagen matrix, collagen powder, foam, and hydrogel. Furthermore, Procyon markets compression garments under the EXTREMIT-EASE name. These offerings are distributed through multiple channels: to institutional clients such as hospitals, wound care clinics, nursing homes, home health agencies, and medical practitioners via distributors, and directly to individual consumers through online sales, direct purchases, and independent or chain pharmacies. Founded in 1987, the company's operations are headquartered in Clearwater, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free